表皮生长因子受体
癌症研究
血管生成
埃罗替尼
酪氨酸激酶
医学
西妥昔单抗
生长因子受体
癌症
ERBB3型
表皮生长因子
受体酪氨酸激酶
信号转导
生物
结直肠癌
受体
内科学
细胞生物学
作者
Agustín Lage,Tania Crombet,Gisela González
出处
期刊:PubMed
日期:2003-01-01
卷期号:35 (5): 327-36
被引量:44
摘要
Epidermal growth factor receptor (EGFR), a member of a family of membrane receptors with tyrosine kinase activity, is emerging as a target candidate for anti-cancer therapy, due to its overexpression in many carcinomas and its relationship with several hallmark properties of malignant behavior such as continuous cell proliferation, escape from apoptosis, cell migration and angiogenesis. Specially appealing is the overexpression of EGFR in tumors such as lung, colon, kidney and head and neck carcinomas which are mostly resistant to current chemotherapy. Several anti-EGFR agents are already in clinical testing: small molecule tyrosine kinases inhibitors, monoclonal antibodies and cancer vaccines. Early results provide evidence of antitumor activity in humans, to be confirmed in larger trials. Toxicity profiles do not overlap with chemotherapy or radiotherapy, but skin rash and diarrhea can be severe. Future investigations should clarify optimal schedules and explore combinations with standard onco-specific treatments. The ultimate challenge will be to combine diverse therapeutic interventions dealing with a regulatory system which is complex, highly redundant and robust. Combinations between vaccines and antibodies, or between vaccines to several molecular components of the system should be evaluated, as well as combinations between inhibitors of the EGFR signaling pathway and inhibitors of other regulatory pathways related to cell proliferation, apoptosis and angiogenesis.
科研通智能强力驱动
Strongly Powered by AbleSci AI